Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe short answer is no. Breastfeeding while taking Wegovy is not recommended, and the medicine's licensed guidance is clear on this point. Semaglutide passes into breast milk in animal studies, and its effects on a nursing infant are not yet known. Until that safety picture is established, the guidance from the NHS medicines page for semaglutide is unambiguous: do not use Wegovy if you are breastfeeding. This is a prescription-only medicine, and any decision about starting, pausing or stopping treatment around breastfeeding must be made with your prescriber or GP, who can weigh your individual circumstances properly.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
This is the biggest misunderstanding our prescribers encounter around Wegovy and feeding. Because semaglutide is injected rather than swallowed, some people assume very little reaches breast milk. The pharmacology doesn't support that comfort. In animal studies, semaglutide was detected in milk, and the infant dose through breast milk is genuinely unknown in humans. That gap in the evidence is exactly why regulators take the precautionary position they do.
There is a second, separate concern that is easy to miss. Wegovy works partly by reducing appetite substantially. A breastfeeding parent already has increased caloric needs, and unintentional calorie restriction on top of that could affect both milk production and the nutritional quality of what is produced. These two issues together, the unknown drug exposure and the appetite suppression, are why the guidance isn't a soft 'use with caution' but a clear 'do not use'.
The NHS semaglutide page and the medicine's Summary of Product Characteristics both reflect this. If you're reading this while still pregnant and thinking ahead, the position on Wegovy during pregnancy is equally firm.
The question most people are really asking is: how long do I need to wait? There are two timelines that matter.
First, breastfeeding itself. The straightforward position is that treatment should not begin until you have fully weaned, and our dedicated page on Wegovy and breastfeeding sets out the detail behind that position, including the appetite suppression concern and what the current evidence base does and does not tell us. There is no published human data that defines a 'safe window' partway through breastfeeding; the precautionary guidance covers the whole period. Discuss the exact timing with your GP or midwife, since individual weaning timelines vary.
Second, the wash-out period before trying to conceive. If you plan to have another pregnancy, semaglutide should be stopped at least two months before you start trying, to allow the medicine to clear your system. The guidance on falling pregnant while on Wegovy covers this in more detail, including what to do if you discover a pregnancy unexpectedly.
Once you've weaned, stopped the medicine where relevant, and are no longer in that planning window, a prescriber can reassess whether Wegovy suits you. That assessment looks at your BMI, any weight-related health conditions, and your full medical history, the medicine is licensed for adults with a BMI of 30 or above, or 27 and above alongside a qualifying condition. Lower thresholds apply for some ethnic backgrounds under UK guidance.
If you are currently breastfeeding and have been prescribed Wegovy elsewhere, or transferred a prescription, do not continue without speaking to the prescribing clinician first. The same applies if you started treatment before a pregnancy you didn't anticipate. Your prescriber needs to know your situation so they can manage the stop safely and advise on monitoring.
If you're currently breastfeeding and researching for when the time is right, that forward-planning approach is sensible. The full Wegovy overview explains how the medicine works, what the trial data shows on average weight outcomes, and what the treatment journey looks like, without requiring a commitment at this stage. The NHS England guidance on weight management injections also covers contraception and timing questions for people planning future treatment.
When the time does come, a consultation with a GPhC-registered Independent Prescriber is the starting point. A real clinician reads every set of answers before any prescription is issued, there is no automated decision-making. If breastfeeding has recently ended and you're not sure about timing, that prescriber conversation is exactly the right place to raise it. You can also read about how breastfeeding and semaglutide interact in more depth before you get there.
One practical note: if treatment is eventually approved, you may also be wondering whether habits like having a glass of wine need to change, and our page on drinking while on Wegovy explains what the guidance says and why it matters. A plain, unbranded box arrives via DPD with tracking to your phone, no indication on the packaging of what's inside. That detail won't matter right now, but it's worth knowing for when it is relevant.
If you have questions about timing, eligibility or anything else, our clinical team is available seven days a week. You can also get in touch directly before starting a formal consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.